SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Apr 7, 2020
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: April 7, 2020 · CIK: 0001659617 · Accession: 0001659617-20-000092
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235686
Letter
Re: Moleculin Biotech, Inc.
Document
April 7, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form S-3
Registration No. 333-235686
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on April 9, 2020, or as soon thereafter as possible on such date.
Very truly yours,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP 1 filename1.htm Document April 7, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Moleculin Biotech, Inc. Registration Statement on Form S-3 Registration No. 333-235686 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on April 9, 2020, or as soon thereafter as possible on such date. Very truly yours, Moleculin Biotech, Inc. By: /s/ Jonathan P. Foster Name: Jonathan P. Foster Title: Chief Financial Officer DC\82195168.1